U.S. stock market update: Cyclacel Pharma down 7.32%

U.S. Stock Market Midday Update Cyclacel Pharma fell 7.32%, with increased trading volume. Based on recent important news: On July 28, Liminatus Pharma announced a strategic expansion into the cryptocurrency and blockchain sectors, planning to raise $500 million for long-term investments, which increased market attention on the biopharmaceutical industry, leading to fluctuations in Cyclacel's stock price. On July 28, executives of CEL-SCI Corporation purchased common stock of the company, enhancing market confidence in the biopharmaceutical industry, affecting Cyclacel's stock price. On July 29, directors of CEL-SCI Corporation again purchased common stock of the company, further boosting market confidence, affecting Cyclacel's stock price. Stocks with High Trading Volume in the Industry Replimune rose 90.80%, with a trading volume of $1.292 billion. Based on recent important news: On July 30, Replimune's RP1 drug was unexpectedly rejected in the BLA application, but due to Prasad's departure, analysts believe the chances of accelerated approval for RP1 have greatly increased, causing the stock price to surge. On July 28, Replimune presented new analysis results of the RP1 and Nivolumab combination therapy at the ASCO annual meeting, leading to positive market outlook and driving the stock price up. On July 29, several law firms announced a class action lawsuit against Replimune; nevertheless, investor confidence in the company's future remained unaffected, and the stock price continued to rise. Sarepta Therapeutics rose 7.26%, with increased trading volume. Based on recent important news: On July 29, the FDA recommended lifting the suspension on Sarepta's gene therapy Elevidys, causing the stock price to rise by 41.05%. On July 30, Barclays raised Sarepta's target price from $10 to $22. On July 29, JP Morgan and Oppenheimer upgraded Sarepta's rating, expecting Elevidys sales to reach $500 million to $600 million. Alnylam Pharmaceuticals rose 2.92%, with increased trading volume. Based on recent important news: On June 26, Needham raised Alnylam Pharmaceuticals' target price from $320 to $377, reflecting market confidence in its RNAi therapy, driving the stock price up. On June 26, a block trade of Sinovac Biotech was discounted by 12.01%, indicating increased market attention on the pharmaceutical industry. On June 20, the stock of Zai Lab-B opened high at 73.8% in the dark market, reflecting positive market expectations for new drug launches Stocks Ranked Among the Top by Market Capitalization in the Industry AbbVie fell 1.28%, with increased trading volume. Based on recent key news: On July 29, Eli Lilly announced that its drug Jaypirca successfully challenged AbbVie's Imbruvica in a Phase III clinical trial, putting pressure on AbbVie's stock price. On July 30, AbbVie released positive Phase III trial results for its drug Upadacitinib, but it failed to fully offset market concerns about competing drugs. On July 30, analysts expected AbbVie's upcoming quarterly earnings report might disappoint, further dragging down the stock price